{
    "clinical_study": {
        "@rank": "77509", 
        "arm_group": {
            "arm_group_label": "Treatment (ixabepilone)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "Phase II trial to study the effectiveness of BMS-247550 in treating patients who have liver\n      or gallbladder cancer. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die."
        }, 
        "brief_title": "BMS-247550 in Treating Patients With Liver or Gallbladder Cancer", 
        "completion_date": {
            "#text": "November 2009", 
            "@type": "Actual"
        }, 
        "condition": [
            "Adult Primary Cholangiocellular Carcinoma", 
            "Adult Primary Hepatocellular Carcinoma", 
            "Advanced Adult Primary Liver Cancer", 
            "Cholangiocarcinoma of the Extrahepatic Bile Duct", 
            "Cholangiocarcinoma of the Gallbladder", 
            "Localized Extrahepatic Bile Duct Cancer", 
            "Localized Gallbladder Cancer", 
            "Localized Resectable Adult Primary Liver Cancer", 
            "Localized Unresectable Adult Primary Liver Cancer", 
            "Recurrent Adult Primary Liver Cancer", 
            "Recurrent Extrahepatic Bile Duct Cancer", 
            "Recurrent Gallbladder Cancer", 
            "Unresectable Extrahepatic Bile Duct Cancer", 
            "Unresectable Gallbladder Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Liver Neoplasms", 
                "Gallbladder Neoplasms", 
                "Bile Duct Neoplasms", 
                "Cholangiocarcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Determine the objective response rate of patients with hepatobiliary cancer treated with\n      BMS-247550.\n\n      II. Determine the toxicity of this drug in these patients. III. Determine the duration of\n      response, median and overall survival, and time to progression in patients treated with this\n      drug.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days for at\n      least 2 courses in the absence of disease progression or unacceptable toxicity.\n\n      Patients are followed every 6 weeks until disease progression"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed locally advanced, metastatic, or recurrent\n             hepatobiliary cancer\n\n               -  Liver (hepatocellular)\n\n               -  Bile duct (cholangiocarcinoma)\n\n               -  Gallbladder\n\n          -  At least 1 unidimensionally measurable lesion\n\n               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan\n\n               -  The following are not considered measurable lesions:\n\n                    -  Lesions seen on colonoscopic examination or barium studies\n\n                    -  Bone metastases\n\n                    -  CNS lesions\n\n                    -  Ascites\n\n          -  No brain metastases\n\n          -  Performance status - ECOG 0-2\n\n          -  At least 3 months\n\n          -  WBC at least 3,000/mm^3\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  AST/ALT no greater than 2.5 times upper limit of normal\n\n          -  Creatinine no greater than 1.5 mg/dL\n\n          -  Creatinine clearance at least 60 mL/min\n\n          -  No symptomatic congestive heart failure\n\n          -  No unstable angina pectoris\n\n          -  No cardiac arrhythmia\n\n          -  No grade 2 or greater peripheral neuropathy\n\n          -  No other uncontrolled concurrent illness\n\n          -  No ongoing or active infection\n\n          -  No psychiatric illness or social situation that would preclude study compliance\n\n          -  No prior allergic hypersensitivity reaction attributed to compounds containing\n             Cremophor EL (e.g., paclitaxel or compounds of similar chemical or biological\n             composition to BMS-247550)\n\n          -  No other currently active malignancy except nonmelanoma skin cancer, carcinoma in\n             situ of the cervix, or cancer for which patient has completed therapy and is at less\n             than 30% risk of relapse\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  No concurrent immunotherapy\n\n          -  No prior chemotherapy\n\n          -  No other concurrent chemotherapy\n\n          -  No concurrent hormonal therapy\n\n          -  No concurrent therapeutic radiotherapy\n\n          -  At least 30 days since prior investigational agents\n\n          -  At least 7 days since prior cimetidine\n\n          -  No concurrent cimetidine\n\n          -  No other concurrent commercial or investigational anticancer agents or therapies\n\n          -  No concurrent unconventional therapies, food, or vitamin supplements (e.g., St.\n             John's Wort)\n\n          -  No concurrent combination antiretroviral therapy for HIV-positive patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 13, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00023946", 
            "org_study_id": "NCI-2012-02407", 
            "secondary_id": [
                "NCI-2012-02407", 
                "CDR0000068878", 
                "NCI-3656", 
                "UCCRC-11045", 
                "UC#11045A", 
                "3656", 
                "P30CA014599", 
                "N01CM62201"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (ixabepilone)", 
                "description": "Given IV", 
                "intervention_name": "ixabepilone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BMS-247550", 
                    "epothilone B lactam", 
                    "Ixempra"
                ]
            }, 
            {
                "arm_group_label": "Treatment (ixabepilone)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Epothilone B", 
                "Epothilones"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60637"
                }, 
                "name": "University of Chicago"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial Of The Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Hepatobiliary Cancer", 
        "overall_official": {
            "affiliation": "University of Chicago", 
            "last_name": "Hedy Kindler", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "A 10% response rate precludes further study whereas a 25% response rate would indicate that further study is warranted.", 
                "measure": "Objective response rate (partial or complete response) evaluated by RECIST", 
                "safety_issue": "No", 
                "time_frame": "Up to 8 years"
            }, 
            {
                "measure": "Frequency and extent of cytotoxic activity graded according to the NCI CTC Version 2.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8 years"
            }, 
            {
                "description": "Will also be evaluated using the Kaplan-Meier estimator.", 
                "measure": "Time to disease progression", 
                "safety_issue": "No", 
                "time_frame": "From the first day of treatment until the date PD or death is first reported, assessed up to 8 years"
            }, 
            {
                "description": "Will also be evaluated using the Kaplan-Meier estimator.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From the time measurement criteria are met for CR/PR (whichever is first recorded) until the first date that PD is objectively documented, assessed up to 10 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00023946"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 2001", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }, 
    "geocoordinates": {
        "University of Chicago": "41.878 -87.63"
    }
}